Showing 14,101 - 14,120 results of 21,342 for search '(( significantly ((larger decrease) OR (nn decrease)) ) OR ( significant decrease decrease ))', query time: 0.60s Refine Results
  1. 14101

    Bias risk assessment of included studies. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  2. 14102

    Forest plot for hs-CRP. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  3. 14103

    Forest plot for IL-6. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  4. 14104

    Antibodies used for flow cytometry. by Shanhe Liu (5251313)

    Published 2025
    “…</p><p>Results</p><p>Flow cytometry analysis revealed a significantly higher apoptosis rate in AN-LSCs compared to LSCs (p < 0.0001). …”
  5. 14105

    The incidence rate of adverse reactions. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  6. 14106

    The PRISMA study flowchart. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  7. 14107

    Forest plot for FEV1/FVC. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  8. 14108

    Primer pairs used for qPCR. by Shanhe Liu (5251313)

    Published 2025
    “…</p><p>Results</p><p>Flow cytometry analysis revealed a significantly higher apoptosis rate in AN-LSCs compared to LSCs (p < 0.0001). …”
  9. 14109

    Forest plot for clinical efficacy. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  10. 14110

    Forest plot for FEV1. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  11. 14111

    The excluded and included studies were listed. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  12. 14112

    Forest plot for PaCO<sub>2</sub>. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  13. 14113

    Forest plot for PaO<sub>2</sub>. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  14. 14114

    Table 1_An alternative structured weight management protocol to rapid weight loss in mixed martial arts: a prospective interventional study of pre-competition weight management str... by Clóvis Albuquerque Maurício (22389121)

    Published 2025
    “…Starting 7 days before the weigh-in, athletes consumed 7 liters of fluids per day, with intake gradually decreasing. On the day before the weigh-in, they consumed only 0.5 liters. …”
  15. 14115

    Data Sheet 1_An alternative structured weight management protocol to rapid weight loss in mixed martial arts: a prospective interventional study of pre-competition weight managemen... by Clóvis Albuquerque Maurício (22389121)

    Published 2025
    “…Starting 7 days before the weigh-in, athletes consumed 7 liters of fluids per day, with intake gradually decreasing. On the day before the weigh-in, they consumed only 0.5 liters. …”
  16. 14116

    Menadiol diacetate mediated subcellular Cd accumulation and nutrients uptake alleviates Cd toxicity and increases growth and yield of summer squash by Wajeeha Yaseen (20278314)

    Published 2024
    “…</p> <p>Some subcellular compartments may serve as storage sites for Cd, helping to decrease the Cd toxicity by sequestering it away from more sensitive cellular components. …”
  17. 14117

    GABA catabolic pathway in <i>Drosophila</i> blood-progenitor cells control their GSH levels. by Manisha Goyal (6339704)

    Published 2025
    “…DNA is stained with DAPI in blue, dome marks the progenitor cells in green. Comparisons for significance are done with their respective control. …”
  18. 14118

    Table1_Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.docx by Min Zhang (111999)

    Published 2024
    “…The most common adverse events were myelosuppression, decreased liver function, fatigue, diarrhea, nausea, and vomiting. …”
  19. 14119

    多杀性巴氏杆菌流行过程中水平基因转移对其毒力与耐药的影响-附录.xlsx by He Jiao (19924953)

    Published 2024
    “…The transcription levels of iron acquisition systems such as fecABCDE, sitABCD operons, and dppAB were also significantly reduced, but the afuAB-dependent periplasmic binding protein-mediated iron transport mechanism was significantly upregulated. …”
  20. 14120

    Study group background characteristics. by Zicheng Hu (3825313)

    Published 2024
    “…This ratio was disrupted when blood CD4+ T-cells fell to <50 cells/μL and the CSF WBC count decreased to negligible levels; in this group the CSF:blood HIV-1 RNA ratio decreased nearly 10-fold to an overall ratio of <1:100. …”